India Starts Making Key API Clavulanic Acid

New Delhi: India has started producing blockbuster clavulanic acid for the first time in what could reduce its dependence on China for APIs. Mumbai-based Kinvan has started producing clavulanic acid that goes into making Augmentin, used to treat various bacterial infections, people in the know told ET.

Industry sources say the company has started producing small batches and will begin full scale production of 300 metric tons towards the end of this year.

Kinvan will invest 447.17 crore to build a 300 mt capacity plant to produce clavulanic acid.

Clavulanic acid also (key starting material) is used for manufacturing amoxyclav (combination of two medicines). Its most popular brand is Augmentin. “As of now we are largely dependent on China. With the initiative of the production-linked incentive scheme companies, we will see production of clavulanic acid and Penicillin G by the end of this year. Kinvan is in advanced stages and large scale fermentation is expected by the end of this year. It’s a step in the right direction,” a person in the know said.

Related Posts

  • Pharma
  • June 27, 2025
  • 179 views
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners,…

  • Pharma
  • June 27, 2025
  • 168 views
Sun Pharma ropes in Richard Ascroft as North America CEO

Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO). In a statement shared via LinkedIn, the company said, “We…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

MedTech Zone AMTZ Puts Vizag on the Science Map of India

MedTech Zone AMTZ Puts Vizag on the Science Map of India

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Sun Pharma ropes in Richard Ascroft as North America CEO

Sun Pharma ropes in Richard Ascroft as North America CEO

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen